It has been previously shown that the sequence similarity between a portion of the enve lope glycoprotein 120 (gpl20) from the human immunodeficiency virus type-1 (HIV-1) and several types of human collagen and collagen-like molecules exists. That observation led to the suggestion that the antibodies against the third hypervariable region (V3) of HIV-1 gpl20 (V3-specific antibodies) might have a role in the autoimmune phenomena observed in HIVinfected persons. In this study we have examined the cross-reactivity of the V3-specific anti bodies purified from sera of HIV-infected individuals, sera obtained from the rheumatoid arthritis and systemic lupus erythematosus patients, as well as from the sera of healthy volun teers with the separate chains of a subcomponent of the first component of the human com plement system, Clq. Our results show that the V3-specific antibodies are present in the sera of the HIV-infected individuals, patients suffering of the systemic autoimmune diseases as well as in the sera of healthy volunteers. Whereas these antibodies appeared in the HIV+-sera after antigen challenge, those present in the H IV --sera probably represent the antibod ies that are cross-reactive with the antigen. V3-reactive antibodies can be purified by affinity chromatography and they were highly specific for the V3-peptide. Additionally, they showed cross-reactivity with the separate chains of the human C lq as well as with the chicken colla gen type VI. Possible physiological implications are discussed.
Introduction
The main binding region for the human immu nodeficiency virus type 1 (HIV-1) neutralising an tibodies, i.e. the "principal neutralising determi nant" (PND), is located within the third hypervariable loop in the V3 region of the enve lope glycoprotein, gpl20 Palker et al., 1988; Matsushita et al., 1988) . Infec tion by H IV induces a vigorous immune response, especially against its principal neutralising deter minant, V3 region. The high titer of IgG and IgA antibodies have been detected at the early stage of the H IV -infection (Kozlowski et al., 1994) .
Previously, Metlas and co-workers (Veljkovic and Metlas, 1990; Metlas et al., 1994a) , have re ported the sequence similarity between a portion of HIV-1 gpl20 envelope protein and human im munoglobulin variable region (IgVh). The sim ilarity has been confirmed by several criteria that have led to the suggestion that gpl20 or V3 loop may play a role in autoimmune phenomena, al ready observed in HIV-infected persons (Pinto et al., 1994; Levy J. A., 1993; Muller et al., 1992; Lake et al., 1994; Grant et al., 1990; Veljkovic and M et las, 1993) . In further studies, the sequence homol ogy between a V3 loop of HIV-1 N Y 5 and several types of human collagen, including the collage nous tail of human C lq A chain have been re ported. Affinity purified V3-reactive antibodies from sera of A ID S patients were reactive with the collagen consensus peptide and with human C lq bound to a microtiter plate (Metlas et al., 1994b) . Based on these studies it has been concluded that this level of sequence similarity can cause the anti body cross-reactivity.
The present study should further examine the cross-reactivity of the V3-specific antibodies with purified human C lq. Sera of the HIV-infected in dividuals (H IV +-sera), sera of the rheumatoid ar thritis (R A ) patients, systemic lupus erythemato sus (SL E ) patients and sera of healthy volunteers (NH-sera) were tested for their reactivity with the peptide synthesised according to the sequence of the third hypervariable region of the H IV-1 N Y 5 gp 120 envelope protein (V3-peptide) and with purified human C lq. The V3-specifie antibodies were purified from human sera by affinity chroma tography and their reactivity towards purified hu man C lq was studied as well.
Materials and Methods

Materials
Peptides and proteins
, synthesised according to the sequence of HIV-1 Ny 5 gpl20 third hypevariable region (V3-peptide), then the peptide corresponding to the se quence of the collagenous part of the human C lq A chain (K -K -G -E-A -G -R -P-G -R ) and the con trol peptide (KP) with the sequence unrelated to V3-peptide, were generous gift from Dr. S. Pongor (IC G E B, Trieste, Italy). The subcomponent of the first component of the human complement, C lq , was purified from pool of sera of healthy volun teers, according to the procedure developed at the Institute for Medical Research, Military Medical Academy, Belgrade (Yugoslavia). Protein concen tration in the sample was determined by commer cial BC A protein assay kit (Pierce, Rockford, Illi nois, U SA ). The presence and purity of C lq was examined and confirmed by radial immunodifusion, immunoelectrophoresis and Western blot. Human serum albumin and IgM antibodies were also detected.
Human sera
All human sera were separated after blood co agulation by centrifugation at 1500 x g for 15 min. Human immunodeficiency virus was inactivated by heating of H IV + sera at 56 °C for 60 min. Also all other sera, i.e. sera obtained from rheumatoid arthritis (R A ), systemic lupus erythematosus (SL E ) patients and healthy volunteers (NH) were prepared under the same conditions.
Methods
Peptide coupling to carrier protein (B SA )
Peptide used in this study was coupled to the carrier protein, BSA , by using l-ethyl-3-(dimethyamonopropyl) carbodiimide hydrochloride (ED C ). Briefly, BSA was dissolved in distilled water (2 mg in 200 /d water), and 2 mg of V3-peptide was dissolved in 5 0 0 /d of M ES-buffer (0 .1 m 2-(N-morpholino) ethanesulfonic acid), 0.9% NaCl, 0.02% NaN3, pH 4.5). Solutions were mixed and 10 mg of E D C was added. The reaction mix ture was left at room temperature for 2 h and then dialysed overnight against 1 mM phosphate buf fered saline (PBS). The solution of a coupled pep tide were stored at -2 0°C until use.
Enzyme linked immunosorbent assay (E L ISA ) E L IS A assays were performed in order to deter mine the sera and affinity purified antibody reac tivity with V3-peptide. The antigen -V3-BSA , C lq -B S A or K P-BSA -was bound to 96-well polystyrene microtiter plate by incubation for 2 h at 37 °C in 0.1 m carbonate buffer pH 9.5. After rinsing with 0.1 m phosphate buffered saline (P B S) / 0.5% Tween 20, pH 7.4 buffer, microplates were saturated with 1% B SA solution in PBS for 1 h at room temperature. The plates were rinsed three times and then the primary antibodies were added. RA , SL E , and NH sera were incubated with V 3-B SA diluted 100-fold, whereas the H IV +-sera were diluted 1000 fold with PBS. Anti-human C lq antiserum was incubated with V 3-BSA in var ious dilutions (1:500, 1:1000, 1:1500, 1:2000, and 1:2500). After purification by affinity chromatog raphy (described below) the V3-specific antibod ies were incubated with V 3-BSA and KP-BSA in amount of 0.0625 ^g/well. Primary antibodies were incubated for lh at room temperature, and after rinsing with PBS/0.5% Tween 20, pH 7.4 buffer, secondary horseradish peroxidase (H RP) conju gated anti-IgG or anti-IgM antibody was added. This lh-incubation step was followed by rinsing with PBS. The colour was developed by adding A B T S substrate (0.05% 2,2l-azino-di(3-ethyl)-benzethiazoline sulfonic acid (A BTS), 0.03% H20 2, 0.1 m citrate buffer, pH 4). After 15 min, the reaction was terminated by 0.1 m citrate buffer, pH 1.8, and the absorbance at 405 nm (A405) was measured. All dilutions were made in 0.1 m PBS 0.1% B SA , pH 7.4. Each sample was measured in duplicate, and the mean values of the blank probe were substracted from each individual values. Only those samples showing an A 405 twice higher than the corresponding blank were considered re active towards the antigen.
Affinity purification of antibodies V3-reactive antibodies were affinity purified from H IV +, R A , SLE, and NH sera on the V3-B SA Sepharose prepared according to the manu facturer's instruction. Sera were dialysed over night against PBS, and then incubated with V3-B SA Sepharose for 2 h at 4 °C. After rinsing the resin with PBS, bound antibodies were eluted with 0.1 m acetate buffer, pH 3, and fractions were im mediately neutralised with 2 m Tris (tris-(hydroxymethyl)-aminomethane), pH 9. Elution was moni tored by measuring the absorbance at 280 nm (A 280), and fractions with A 28o values higher 70% of maximal value were collected for further analy ses. Pooled fractions were analysed by SDS-PAGE. Only in sample of antibodies purified from R A sera presence of another protein beside anti bodies was detected.
SD S-PA GE and Western blot
In order to examine the sera and affinity-purified antibody reactivity with separate chains of hu man C lq , sample of purified C lq was resolved on 10% polyacrylamide gel under non-reduced and reduced conditions according to Laemmli (Laemmli, 1970) , and then transferred onto the nitro-cellulose membrane as described in (Towbin et al., 1979) . Briefly, purified C lq was mixed in 1:1 (v : v) ratio with the non-reducing sample buffer (0.2 m Tris, 4% sodium dodecylsulfate (SD S), 20% glycerol, 0.02% bromphenol blue) or with the re ducing buffer (0.2 m Tris, 4% sodium dodecylsul fate (SD S) 20% glycerol, 0.02% bromphenol blue, 6% /3-mercaptoethanol) and left overnight prior to application on gel. After separation, proteins were transferred from gel to nitro-cellulose membrane. After blocking of the membrane with 1% bovine serum albumin for 3 h at room temperature, nitrocelulose membranes were incubated with primary antibodies. Mouse anti-human C lq antiserum was incubated with purified C lq samples separated un der non-reducing (sample buffer did not contain /3-mercaptoethanol) and reducing (sample buffer contained /3-mercaptoethanol) conditions, as well as human sera diluted with tris buffered salt solu tion (0.02 m Tris 0.5 m NaCl, pH 7.5) with 0.05% Tween 20 (T T B S ). Also, affinity-purified antibod ies from H IV +, R A , SL E and NH sera were tested for their reactivity with both forms of the sample of human C lq. Incubation of the sample of C lq with primary antibodies was lh at room temper ature. After washing with T T B S secondary antiIgG and anti-IgM antibodies were incubated with nitro-cellulose sheets, and protein bands were de tected with 3,3'-diaminobenzidine (D A B ) as a substrate (0.03% DAB, 10 mM phosphate buffer, pH 6.5, 0.01% H20 2). Each incubation step was followed by rinsing nitro-cellulose with T T B S (3 times, 5 min each).
Statistical analysis
Comparison of the sera reactivity with the pep tides was done by Student's t-test and if p < 0.05 the difference was considered significant.
Results
Reactivity o f human sera with the V3-peptide
In the first part of our work we have tested hu man sera for their reactivity with the V3-peptide coupled to the carrier protein, BSA . 
the V3-peptide was examined by E L ISA , and the reactivity of IgG and IgM antibodies was detected. All sera showed the reactivity of IgG and IgM an tibodies towards the V3-peptide. The mean value obtained for IgG antibodies of H IV +-sera (0.88 ± 0.35) was higher than that obtained for other sera (0.25 ± 0.07, 0.22 ± 0.07, and 0.16 ± 0.09 for RA , SL E and NH sera, respectively). The mean IgG antibody reactivity of RA -and SLE-sera was not significantly higher in comparison to that mea sured for NH-sera (p < 0.05).
The mean value for IgM antibodies of the RAsera (0.86 ± 0.10) was highest of the IgM antibody reactivity among other human sera tested (0.54 ± 0.3, 0.73 ± 0.10, and 0.37 ± 0.20, for H IV +-, SLEand NH-sera, respectively). Rather high standard deviation is obtained for H IV + sera, especially in the case of IgG antibodies. Only few of the H IV +-sera tested showed lower level of the V3-specific reactivity then NH-sera.
The reactivity o f mouse anti-Clq antiserum with the V3-peptide
In order to obtain more information about the proposed antigenic similarity between two unre lated proteins -gpl20 from H IV -1 N Y 5 and human C lq -mouse antiserum raised against human C lq was tested at various dilutions for its reactivity with V 3-BSA . Fig. 2 shows the reactivity of the IgG antibodies of the mouse anti-Clq antiserum with the V3-peptide tested by E L ISA . The reactiv ity of the anti-Clq antiserum with the V3-peptide decreased with increasing dilution, and the shape of the dilution curve indicates a rather low concen tration of IgG V3-reactive antibodies in the antise rum. However, these data indicate that a certain degree of cross-reactivity of the anti-human C lq antiserum with the V3-peptide exists.
The reactivity o f the human sera and the affinitypurified antibodies with V3-and Clq-peptide
In the next step of our experiments we have purified the V3-reactive antibodies from human sera by affinity chromatography as described in the "Materials and Methods" section. Fig. 3a shows the yield of the V3-specific antibodies from H IV +-, RA -, SLE-and NH-sera calculated per volume of the applied serum. The highest yield of proteins was obtained from H IV +-sera, whereas the lowest amount of proteins was purified by af finity chromatography from NH-sera. Purified an tibodies were tested for their reactivity against V3-peptide by EL ISA . The results presented in Fig. 3b show that both IgG and IgM antibodies were puri fied from sera. By comparison the reactivity of an individual antibody class, the results are in accor dance with those obtained with sera (cf. Fig. 1 ): The IgG antibodies from H IV +-sera were of the highest reactivity (all affinity-purified antibodies were applied at the same concentration) . The IgM antibodies of the RA-sera were the most reactive with V3-peptide among other IgM antibodies.
In order to check the specificity of the affinitypurified antibodies, all samples were tested for their reactivity towards the unrelated peptide, con trol peptide (K P-BSA ). In Fig. 3c , the reactivity of the V3-specific antibodies purified from human sera towards K P-BSA is presented. The control peptide used in our study has the same amino acid composition as V3-peptide but with different se quence, and was used as a control for the antibody specificity. All affinity-purified antibodies showed low reactivity with KP-BSA . The highest reactivity was detected in the sample purified from RA-sera (IgM antibodies) and it does not exceed 20% of the same antibody reactivity with V3-peptide (Fig. 3b) .
H IV +-and NH-sera as well as the affinity-purified V3-specific antibodies from H IV +-and NH- sera were tested for their reactivity with the C lq peptide that shares the sequence homology with the V3-peptide. The reactivity of IgG antibodies was detected by E L IS A and under our experimen tal conditions we detected only small IgG antibody reactivity with the Clq-peptide in the human sera (Fig. 4) , whereas the same sera contained still higher reactivity with V3-peptide. On the other hand, the affinity purified V3-specific antibodies failed to react with the Clq-peptide, but reacted with the V3-peptide (Fig. 4) .
Additionally, all antibodies were tested for their reactivity towards the peptide synthesised accord ing to the similar region on collagen type II. The NH and H IV + sera showed weak reactivity with the peptide (data not shown). In accordance to the results obtained with the V3-specific antibody re activity against the Clq-peptide, reactivity of the affinity purified V3-specific antibodies was not de tected with the peptide synthesised according to the sequence homologous to V3 of the human col lagen type II (data not shown).
The reactivity o f human sera and the affinity-puri fied antibodies with human C lq
The reactivity of H IV +-, R A -, SLE-and NHsera with human C lq was examined by Western blotting. Human C lq was purified from a pool of sera of healthy volunteers. The human serum albu min and IgM antibody were also detected (data not shown). The presence of human C lq was con firmed by positive reaction with anti-human C lq antiserum by immunoelectrophoresis, immunodif fusion and Western blotting.
The sera reactivity with the purified C lq sepa rated electrophoretically under non-reducing and reducing conditions was tested. None of the sera examined showed neither IgG nor IgM antibody reactivity with non-reduced C lq (data not shown). Also, the H IV +-and NH-sera did not react with the reduced sample of human C lq under our ex- perimental conditions (Fig. 5a ), whereas RA -and SLE-sera appeared to be reactive with the sepa rate chains of the reduced human C lq (Fig. 5a) . Additionally, R A -sera showed primarily the reac tivity of IgM antibody, whereas SLE-sera showed both IgG and IgM antibody reactivity against re duced sample of purified human C lq.
Accordingly, the reactivity of the affinity-purified, V3-specific antibodies, against purified C lq that was electrophoretically separated under non reducing conditions was not detected (data not shown). On the other hand, IgG and IgM V3-specific antibodies from all human sera -H IV +, RA , SL E and NH -were reactive with A-and Bchains of the reduced C lq (Fig. 5b) . The individual chains of human C lq -A, B and C -were recog nised according to their molecular masses.
In separate experiments, human sera as well as the affinity purified V3-specific antibodies were tested for their reactivity with the chicken collagen type VI by E L ISA . The protein was bound to the microtiter plate, and the reactivity of both IgG and IgM antibodies was detected. Whereas all sera failed to react with the chicken collagen type VI (data not shown), the affinity-purified, V3-specific antibodies showed slight reactivity of IgG and IgM antibodies (data not shown). However, their reac tivity was between 5-fold (NH sera) and 15-fold (H IV +-sera) lower than with the V3-peptide as as sessed by the same assay.
Discussion
Antigenic similarity between A chain of human C lq and V3 region of gpl20 was assumed on the basis of high degree of sequence similarity that has been found by Metlas and co-workers (Metlas et  al., 1994a) . Lack of the cross-reactivity between V3-specific antibodies affinity purified from H IV +-, and NH-sera, towards the Clq-peptidesynthesised according to the homologous region of C lq A chain -probably is caused by the absence of some amino acids that might be important for the epitope formation. This assumption was made by the shown cross-reactivity of the V3-specific antibodies with the A chain of human C lq. Addi tionally, the epitope(s) similar to V3 region of gpl20 HIV-1 N Y 5 on human C lq B chain was de tected (Fig. 5b) .
Peptide synthesis and examination of antibody cross-reactivity is a common approach for locating the antigenic determinant or epitope of a particu lar protein. Any linear peptide of 5 -1 0 amino acids that is found to react with antibodies is con sidered a »continuous« epitope. Such an epitope within the protein is formed from the neighbour ing amino acids. On the other hand, the epitopes might be formed from a rather distant amino acids, and those are called »discontinuous«. In some cases, the epitope conformation presented by a peptide, might be important for antibody reactiv ity (Van Regenmortel, 1987) .
High level of the anti-V3 antibodies in HIV-in fected sera was detected in our experiments (Fig. 1) , and the highest amount of V3-rective anti bodies was purified from the H IV +-sera compared to RA , SL E and NH sera (Fig. 3a) . This again indi cates that although a high degree of the sequence similarity between HIV-epitopes and some human proteins exists (Metlas et al., 1994a ) the immune system recognises viral epitopes as foreign deter minants. The immune response initiated against the determinants similar to the V3 might crossreact with closely homologous self-host proteins such as collagens or C lq. Also, the polyclonal mouse anti-human C lq antiserum binds to the V3 peptide (Fig. 2) , and therefore, the cross-reactivity between these molecules with the sequence sim ilarity occurs.
Probably due to the antigenic similarity between host proteins and viral epitope(s), we detected an tibodies reactive with V3 loop-derived peptide, which was not initially present in sera of patients with rheumatoid arthritis and systemic lupus ery thematosus (Fig. 1) . The antibodies were mainly IgM class, while IgG antibodies showed no marked differences compared to control sera, which again suggest the polyclonal activation of B lymphocytes in this systemic autoimmune disor ders (Jefferis, 1995) . We suppose that these are an tibodies raised against C lq or collagen that are often detected in sera of patients with systemic au toimmune diseases Rönnelid and Klareskog, 1995; D'Cruz et al., 1995; Coremans et al., 1995; Wisnieski and Naff, 1989; Siegert et al., 1990) . These antibodies could cross-react with sim ilar epitopes. Anti-collagen and anti-Clq autoanti bodies are directed against those molecules that are conformationally changed or denatured. Only in a few cases autoantibodies directed against native collagen molecules has been detected. (Clague and Moore, 1984; Andriopoulos et al., 1976) .
We detected neither human sera nor affinity purified antibody reactivity with the non-reduced human C lq, which is in accordance with these pre vious reports. In our experiments, the sera failed to react with the chicken collagen type V I bound to the microtiter plate, most probably due to the low number of epitopes exposed in this non-denatured proteins. However, the low but detectable cross-reactivity of the V3-specific antibodies puri fied from human sera with the same protein, indi cates that the V3-similar epitopes also exist on the chicken collagen type VI.
Results of numerous authors suggest that auto antibody production against these determinants is a secondary event compared to the inflammatory reactions. Presence of the enzymes and reactive oxygen species released during immune reaction against infection might damage C lq , which is also involved in defence mechanism. Changes in con formation C lq might expose its cryptic epitopes to the immune system. In addition, it has been shown that after limited proteolysis of C lq by leukocyte collagenase this protein is antigenically similar to collagen type II (Heinz et al., 1988; Heinz et al., 1989) . We detected the reactivity of the affinity purified antibodies only with a reduced sample of C lq (Fig. 5b) , which is in accordance with those findings. Conformational changes induced when unreduced C lq was bound to the nitro-cellulose membrane probably were not sufficient to detect the antibody binding. Additionally, reduction of the antigen leads to detectable antigenic cross-re activity of the V3 reactive antibodies from H IV +-, RA -, SLE-and NH-sera.
IgM anti-gpl20 antibodies were detected in sera of healthy individuals, and it appears that they are a part of normal immune repertoire (Pinto et al., 1994) . In our studies we detected IgM V3 reactive antibodies in sera of healthy volunteers (Fig. 1) . Very low IgG reactivity in control sera was found. Very recently, the presence of the V3-reactive IgG antibodies in normal human sera was described (Metlas et al, 1999a; Metlas et al, 1999b) . In sera of HIV-infected individuals numerous autoreac tive antibodies are detected and it has been sug gested that autoimmune phenomena may partici pate in disease progression. Autoantibodies found in sera of HIV-infected persons are suggested to be triggered by viral antigens with similar anti genic properties with self-host proteins (D eBari and Akl, 1994; Gotoh and Matsuda, 1995; Lake et al., 1994; Müller et al., 1994; Theofilopoulos, 1995) . This is one more report about unrelated pro teins whose antigenic homology, proposed on the basis of their sequence homology is experimen tally shown. Further studies must be performed considering the structural motifs on human C lq B chain which are responsible for antigenic similarity with the third hypervariable region of H IV-1 N Y 5 gp 120. 
